Interleukin-6 receptor blockade in patients with COVID-19: placing clinical trials into context

Federico Angriman, Bruno L Ferreyro, Lisa Burry, Eddy Fan, Niall D Ferguson, Shahid Husain, Shaf H Keshavjee, Enrico Lupia, Laveena Munshi, Samuele Renzi, Onion Gerald V Ubaldo, Bram Rochwerg, Lorenzo Del Sorbo, Federico Angriman, Bruno L Ferreyro, Lisa Burry, Eddy Fan, Niall D Ferguson, Shahid Husain, Shaf H Keshavjee, Enrico Lupia, Laveena Munshi, Samuele Renzi, Onion Gerald V Ubaldo, Bram Rochwerg, Lorenzo Del Sorbo

Abstract

The pleiotropic cytokine interleukin-6 (IL-6) has been implicated in the pathogenesis of COVID-19, but uncertainty remains about the potential benefits and harms of targeting IL-6 signalling in patients with the disease. The efficacy and safety of tocilizumab and sarilumab, which block the binding of IL-6 to its receptor, have been tested in adults with COVID-19-related acute respiratory illness in randomised trials, with important differences in trial design, characteristics of included patients, use of co-interventions, and outcome measurement scales. In this Series paper, we review the clinical and methodological heterogeneity of studies of IL-6 receptor antagonists, and consider how this heterogeneity might have influenced reported treatment effects. Timing from clinical presentation to treatment, severity of illness, and concomitant use of corticosteroids are among the factors that might have contributed to apparently inconsistent results. With an understanding of the sources of variability in these trials, available evidence could be applied to guide clinical decision making and to inform the enrichment of future studies.

Conflict of interest statement

Declaration of interests EF reports personal fees from ALung Technologies, Baxter, Getinge, and MC3 Cardiopulmonary, outside of the submitted work. NDF reports personal fees from Xenios and Baxter, outside of the submitted work. All other authors declare no competing interests.

Copyright © 2021 Elsevier Ltd. All rights reserved.

Figures

Figure
Figure
Proposed use of IL-6R blockade in patients with COVID-19-associated hypoxaemic respiratory failure A conceptual model of the time-course of infection from the asymptomatic phase to more severe phases in patients who develop critical illness. The model includes completed RCTs and the main physiological features of disease in each phase. We propose a potential time window in which IL-6R blockade might be more effective. The length of each RCT box is proportional to the time from symptom onset or hospitalisation to randomisation in each trial population, and the location corresponds to the severity, on average, of enrolled patients. For many patients, the progression from the asymptomatic phase to critical illness occurs in a short period of time, and the current representation might not be applicable in the case of rapid progression. Trials that appear in light orange are those that were positive for the primary outcome. ICU=intensive care unit. IL-6R=interleukin-6 receptor. RCT=randomised controlled trial. Figure originally created using BioRender.

References

    1. Garbers C, Heink S, Korn T, Rose-John S. Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov. 2018;17:395–412.
    1. Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383:2255–2273.
    1. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388:2023–2038.
    1. Schoels MM, Van Der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72:583–589.
    1. Choy EH, De Benedetti F, Takeuchi T, Hashizume M, John MR, Kishimoto T. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16:335–345.
    1. Piroth L, Cottenet J, Mariet AS, et al. Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study. Lancet Respir Med. 2021;9:251–259.
    1. Lim ZJ, Subramaniam A, Reddy MP, et al. Case fatality rates for patients with COVID-19 requiring invasive mechanical ventilation. Am J Respir Crit Care Med. 2021;203:54–66.
    1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
    1. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to management warranted? Lancet Respir Med. 2020;8:816–821.
    1. Leisman DE, Ronner L, Pinotti R, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med. 2020;8:1233–1244.
    1. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324:782–793.
    1. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.
    1. Thachil J, Tang N, Gando S, et al. ISTH interim guidance on recognition and management of coagulopathy in COVID-19. J Thromb Haemost. 2020;18:1023–1026.
    1. Campochiaro C, Dagna L. The conundrum of interleukin-6 blockade in COVID-19. Lancet Rheumatol. 2020;2:e579–e580.
    1. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. Chest. 2020;158:1397–1408.
    1. Guirao JJ, Cabrera CM, Jiménez N, Rincón L, Urra JM. High serum IL-6 values increase the risk of mortality and the severity of pneumonia in patients diagnosed with COVID-19. Mol Immunol. 2020;128:64–68.
    1. Zhu J, Pang J, Ji P, et al. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. J Med Virol. 2021;93:35–37.
    1. Gupta S, Wang W, Hayek SS, et al. Association between early treatment with tocilizumab and mortality among critically ill patients with COVID-19. JAMA Intern Med. 2021;181:41–51.
    1. Biran N, Ip A, Ahn J, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2:e603–e612.
    1. Hermine O, Mariette X, Tharaux PL, Resche-Rigon M, Porcher R, Ravaud P. Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:32–40.
    1. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial. JAMA Intern Med. 2021;181:24–31.
    1. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of tocilizumab in patients hospitalized with Covid-19. N Engl J Med. 2020;383:2333–2344.
    1. Veiga VC, Prats JAGG, Farias DLC, et al. Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial. BMJ. 2021;372:n84.
    1. Salama C, Han J, Yau L, et al. Tocilizumab in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;384:20–30.
    1. Rosas IO, Bräu N, Waters M, et al. Tocilizumab in hospitalized patients with severe Covid-19 pneumonia. N Engl J Med. 2021;384:1503–1516.
    1. The REMAP-CAP Investigators Interleukin-6 receptor antagonists in critically ill patients with Covid-19. N Engl J Med. 2021;384:1491–1502.
    1. Horby PW, Pessoa-Amorim G, Peto L, et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial. medRxiv. 2021 doi: 10.1101/2021.02.11.21249258. published online Feb 11. (preprint).
    1. Soin AS, Kumar K, Choudhary NS, et al. Tocilizumab plus standard care versus standard care in patients in India with moderate to severe COVID-19-associated cytokine release syndrome (COVINTOC): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00081-3. published online March 4.
    1. Lescure F-X, Honda H, Fowler RA, et al. Sarilumab treatment of hospitalised patients with severe or critical COVID-19: a multinational, randomised, adaptive, phase 3, double-blind, placebo-controlled trial. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00099-0. published online March 4.
    1. Parr JB. Time to reassess tocilizumab's role in COVID-19 pneumonia. JAMA Intern Med. 2021;181:12–15.
    1. Murthy S, Lee TC. IL-6 blockade for COVID-19: a global scientific call to arms. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00127-2. published online March 4.
    1. Imrey PB. Limitations of meta-analyses of studies with high heterogeneity. JAMA Netw Open. 2020;3
    1. Bhatt DL, Mehta C. Adaptive designs for clinical trials. N Engl J Med. 2016;375:65–74.
    1. Chen SL, Feng HY, Xu H, et al. Patterns of deterioration in moderate patients with COVID-19 from Jan 2020 to Mar 2020: a multi-center, retrospective cohort study in China. Front Med (Lausanne) 2020;7
    1. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–1062.
    1. Manson JJ, Crooks C, Naja M, et al. COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. Lancet Rheumatol. 2020;2:e594–e602.
    1. Castelnovo L, Tamburello A, Lurati A, et al. Anti-IL6 treatment of serious COVID-19 disease: a monocentric retrospective experience. Medicine (Baltimore) 2021;100
    1. Gandhi RT, Lynch JB, del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383:1757–1766.
    1. The RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 — final report. N Engl J Med. 2020;383:1813–1826.
    1. Wilkinson E. RECOVERY trial: The UK covid-19 study resetting expectations for clinical trials. BMJ. 2020;369
    1. Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) study. Rationale and design. Ann Am Thorac Soc. 2020;17:879–891.
    1. Angriman F, Masse MH, Adhikari NKJ. Defining standard of practice: pros and cons of the usual care arm. Curr Opin Crit Care. 2019;25:498–504.
    1. Knight SR, Ho A, Pius R, et al. Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score. BMJ. 2020;370
    1. Del Valle DM, Kim-Schulze S, Huang HH, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26:1636–1643.
    1. Laing AG, Lorenc A, del Molino del Barrio I, et al. A dynamic COVID-19 immune signature includes associations with poor prognosis. Nat Med. 2020;26:1623–1635.
    1. Herold T, Jurinovic V, Arnreich C, et al. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 2020;146:128. 36.e4.
    1. McElvaney OJ, Curley GF, Rose-John S, McElvaney NG. Interleukin-6: obstacles to targeting a complex cytokine in critical illness. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(21)00103-X. published online April 16.
    1. Guillén L, Padilla S, Fernández M, et al. Preemptive interleukin-6 blockade in patients with COVID-19. Sci Rep. 2020;10
    1. Hernán MA, Sauer BC, Hernández-Díaz S, Platt R, Shrier I. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70–75.
    1. de Cáceres C, Martínez R, Bachiller P, Marín L, García JM. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. Pharmacol Rep. 2020;72:1529–1537.
    1. Walter SD, Guyatt GH, Bassler D, Briel M, Ramsay T, Han HD. Randomised trials with provision for early stopping for benefit (or harm): the impact on the estimated treatment effect. Stat Med. 2019;38:2524–2543.
    1. Yarnell CJ, Abrams D, Baldwin MR, et al. Clinical trials in critical care: can a Bayesian approach enhance clinical and scientific decision making? Lancet Respir Med. 2021;9:207–216.
    1. Rees EM, Nightingale ES, Jafari Y, et al. COVID-19 length of hospital stay: a systematic review and data synthesis. BMC Med. 2020;18:270.
    1. Carneiro CFD, Queiroz VGS, Moulin TC, et al. Comparing quality of reporting between preprints and peer-reviewed articles in the biomedical literature. Res Integr Peer Rev. 2020;5:16.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe